Page last updated: 2024-09-04

moxifloxacin and tetracycline

moxifloxacin has been researched along with tetracycline in 48 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (tetracycline)	Trials (tetracycline)	Recent Studies (post-2010) (tetracycline)
3,157	552	1,690	21,524	977	3,656

Protein Interaction Comparison

Protein	Taxonomy	tetracycline (IC50)
90-kda heat shock protein beta HSP90 beta, partial	Homo sapiens (human)	22.4474
heat shock protein HSP 90-alpha isoform 2	Homo sapiens (human)	22.4474
tyrosine-protein phosphatase non-receptor type 7 isoform 2	Homo sapiens (human)	8.33
30S ribosomal protein S6	Escherichia coli K-12	4.58
30S ribosomal protein S7	Escherichia coli K-12	4.58
50S ribosomal protein L15	Escherichia coli K-12	4.58
50S ribosomal protein L10	Escherichia coli K-12	4.58
50S ribosomal protein L11	Escherichia coli K-12	4.58
50S ribosomal protein L7/L12	Escherichia coli K-12	4.58
50S ribosomal protein L19	Escherichia coli K-12	4.58
50S ribosomal protein L1	Escherichia coli K-12	4.58
50S ribosomal protein L20	Escherichia coli K-12	4.58
50S ribosomal protein L27	Escherichia coli K-12	4.58
50S ribosomal protein L28	Escherichia coli K-12	4.58
50S ribosomal protein L29	Escherichia coli K-12	4.58
50S ribosomal protein L31	Escherichia coli K-12	4.58
50S ribosomal protein L31 type B	Escherichia coli K-12	4.58
50S ribosomal protein L32	Escherichia coli K-12	4.58
50S ribosomal protein L33	Escherichia coli K-12	4.58
50S ribosomal protein L34	Escherichia coli K-12	4.58
50S ribosomal protein L35	Escherichia coli K-12	4.58
50S ribosomal protein L36	Escherichia coli K-12	4.58
30S ribosomal protein S10	Escherichia coli K-12	4.58
30S ribosomal protein S11	Escherichia coli K-12	4.58
30S ribosomal protein S12	Escherichia coli K-12	4.58
30S ribosomal protein S13	Escherichia coli K-12	4.58
30S ribosomal protein S16	Escherichia coli K-12	4.58
30S ribosomal protein S18	Escherichia coli K-12	4.58
30S ribosomal protein S19	Escherichia coli K-12	4.58
30S ribosomal protein S20	Escherichia coli K-12	4.58
30S ribosomal protein S2	Escherichia coli K-12	4.58
30S ribosomal protein S3	Escherichia coli K-12	4.58
30S ribosomal protein S4	Escherichia coli K-12	4.58
30S ribosomal protein S5	Escherichia coli K-12	4.58
30S ribosomal protein S8	Escherichia coli K-12	4.58
30S ribosomal protein S9	Escherichia coli K-12	4.58
50S ribosomal protein L13	Escherichia coli K-12	4.58
50S ribosomal protein L14	Escherichia coli K-12	4.58
50S ribosomal protein L16	Escherichia coli K-12	4.58
50S ribosomal protein L23	Escherichia coli K-12	4.58
30S ribosomal protein S15	Escherichia coli K-12	4.58
50S ribosomal protein L17	Escherichia coli K-12	4.58
50S ribosomal protein L21	Escherichia coli K-12	4.58
50S ribosomal protein L30	Escherichia coli K-12	4.58
50S ribosomal protein L6	Escherichia coli K-12	4.58
30S ribosomal protein S14	Escherichia coli K-12	4.58
30S ribosomal protein S17	Escherichia coli K-12	4.58
30S ribosomal protein S1	Escherichia coli K-12	4.58
50S ribosomal protein L18	Escherichia coli K-12	4.58
Alpha-synuclein	Homo sapiens (human)	6.06
50S ribosomal protein L2	Escherichia coli K-12	4.58
50S ribosomal protein L3	Escherichia coli K-12	4.58
50S ribosomal protein L24	Escherichia coli K-12	4.58
50S ribosomal protein L4	Escherichia coli K-12	4.58
50S ribosomal protein L22	Escherichia coli K-12	4.58
50S ribosomal protein L5	Escherichia coli K-12	4.58
30S ribosomal protein S21	Escherichia coli K-12	4.58
50S ribosomal protein L25	Escherichia coli K-12	4.58
50S ribosomal protein L36 2	Escherichia coli K-12	4.58

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (50.00)	29.6817
2010's	23 (47.92)	24.3611
2020's	1 (2.08)	2.80

Authors

Authors	Studies
Duewelhenke, N; Eysel, P; Krut, O	1
Frank, KL; Patel, R; Piper, KE; Reichert, EJ	1
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA	1
Courvalin, P; Galimand, M; Périchon, B	1
Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH	1
Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K	1
Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Brémont, S; Courvalin, P; Damier-Piolle, L; Lambert, T; Magnet, S	1
Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Cattoir, V; Nordmann, P; Poirel, L	1
Crabb, DM; Duffy, LB; Waites, KB	1
Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS	1
Hamasuna, R; Jensen, JS; Osada, Y	1
Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A	1
Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Ardanuy, C; Brito-Avô, A; Gonçalo-Marques, J; Liñares, J; Morais, A; Pires, R; Rolo, D; Santos-Sanches, I	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Zhang, T	1
Erhard, A; Imhoff, JF; Kajahn, I; Nagel, K; Ohlendorf, B; Schneemann, I; Wiese, J; Zinecker, H	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W	1
Brooke, CJ; Hampson, DJ; Riley, TV	1
Eisenblätter, M; Hahn, H; Ignatius, R; Jabbusch, M; Wagner, J; Wendt, C	1
Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL	1
Farny, K; Michault, A; Picot, S; Simac, C	1
Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Song, IS	1
Jung, HC; Kang, JM; Kim, JS; Kim, N; Kim, YR; Lee, DH; Park, YS; Song, IS	1
Bago, J; Bago, P; Bakula, V; Marusić, M; Pevec, B; Tomić, M	1
Akbal, E; Koçak, E; Köklü, S; Taş, A	1
Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS	1
Dan, M; Rosenberg, S; Samra, Z	1
Barbanti, F; Mastrantonio, P; Spigaglia, P	1
Ergül, B; Filik, L; Koçak, E; Köklü, S; Taş, A	1
Jo, HJ; Kim, MS; Kim, N; Kim, SE; Lee, DH; Park, YS; Shin, CM	1
Jo, HJ; Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS	1
Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM	1
Choi, YJ; Kim, N; Kwon, YH; Lee, DH; Lee, JW; Lee, JY; Nam, RH; Suh, JH; Yoon, K	1
Beeton, ML; Chalker, VJ; Jones, LC; Maxwell, NC; Spiller, OB	1
Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A	1
Bernardy, J; Faldyna, M; Krejčí, J; Krutova, M; Matejkova, J; Nyc, O; Tkadlec, J; Zouharova, M	1
Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I	1

Reviews

1 review(s) available for moxifloxacin and tetracycline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

7 trial(s) available for moxifloxacin and tetracycline

Article	Year
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter, 2006, Volume: 11, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline; Treatment Outcome	2006
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter, 2007, Volume: 12, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline	2007
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:1-2 Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Quinolines; Recurrence; Retreatment; Single-Blind Method; Tetracycline; Young Adult	2009
Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study. Helicobacter, 2011, Volume: 16, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Tetracycline; Treatment Outcome; Young Adult	2011
Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:5 Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Quinolines; Tetracycline; Young Adult	2013
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC gastroenterology, 2013, Sep-19, Volume: 13 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Free Survival; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Quinolines; Recurrence; Stomach Neoplasms; Tetracycline; Treatment Outcome	2013
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Tertiary Care Centers; Tetracycline; Young Adult	2016

Other Studies

40 other study(ies) available for moxifloxacin and tetracycline

Article	Year
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:1 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors	2007
In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; DNA, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Nafcillin; Oxazolidinones; Penicillin-Binding Proteins; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus; Tetracycline	2007
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles	2007
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid	2007
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae	2007
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents	2007
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance	2007
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Multigene Family; Sequence Analysis, DNA; Substrate Specificity	2008
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids	2008
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections	2008
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5 Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines	2009
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11 Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction	2009
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes	2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline	2010
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Amino Acid Substitution; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Carrier Proteins; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Molecular Epidemiology; Norfloxacin; Point Mutation; Portugal; Streptococcal Infections; Streptococcus pyogenes	2010
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Anti-Bacterial Agents; Erythromycin; Luminescent Proteins; Microbial Sensitivity Tests; Models, Genetic; Mycobacterium ulcerans; Reserpine; Tetracycline	2010
Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea. Journal of natural products, 2010, Jul-23, Volume: 73, Issue:7 Topics: Animals; Antineoplastic Agents; Benz(a)Anthracenes; Drug Resistance, Bacterial; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Marine Biology; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Polyketide Synthases; Porifera; Stereoisomerism; Streptomyces	2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells	2019
In vitro antimicrobial susceptibility of Brachyspira pilosicoli isolates from humans. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:7 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Chloramphenicol; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Meropenem; Metronidazole; Moxifloxacin; Quinolines; Spirochaetales; Swine; Tetracycline; Thienamycins	2003
Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:7 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Campylobacter jejuni; Ciprofloxacin; Clindamycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Germany; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Tetracycline	2003
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method. Diagnostic microbiology and infectious disease, 2004, Volume: 48, Issue:3 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline	2004
[Antimicrobial resistance of Streptococcus pneumoniae strains isolated in the Reunion Island during 2004]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:1 Topics: Aza Compounds; beta-Lactams; Cephalosporin Resistance; Cephalosporins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Ketolides; Moxifloxacin; Penicillin Resistance; Quinolines; Retrospective Studies; Reunion; Rifampin; Streptococcal Infections; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination	2006
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 57, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline	2011
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum	2011
Multidrug resistance in European Clostridium difficile clinical isolates. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Clindamycin; Clostridioides difficile; Clostridium Infections; DNA Transposable Elements; DNA, Ribosomal; Drug Resistance, Multiple, Bacterial; Erythromycin; Europe; Fluoroquinolones; Humans; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Quinolines; Ribosomal Proteins; Rifampin; RNA, Ribosomal, 23S; Tetracycline	2011
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and liver, 2015, Volume: 9, Issue:4 Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; Treatment Outcome	2015
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. Gut and liver, 2014, Volume: 8, Issue:6 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea	2014
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Bacterial; England; Epidemiological Monitoring; Fluoroquinolones; Gentamicins; Humans; Infant; Infant, Newborn; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tetracycline; Ureaplasma; Ureaplasma Infections; Wales	2016
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult	2016
The emergence of Clostridium difficile PCR ribotype 078 in piglets in the Czech Republic clusters with Clostridium difficile PCR ribotype 078 isolates from Germany, Japan and Taiwan. International journal of medical microbiology : IJMM, 2018, Volume: 308, Issue:7 Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Czech Republic; DNA Gyrase; Germany; Japan; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Swine; Taiwan; Tetracycline; Vancomycin	2018
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:10 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline	2022